Edition:
India

Crinetics Pharmaceuticals Inc (CRNX.OQ)

CRNX.OQ on NASDAQ Stock Exchange Global Select Market

11.92USD
9:24pm IST
Change (% chg)

$-0.56 (-4.49%)
Prev Close
$12.48
Open
$12.20
Day's High
$12.58
Day's Low
$11.71
Volume
20,130
Avg. Vol
63,820
52-wk High
$26.65
52-wk Low
$10.63

Latest Key Developments (Source: Significant Developments)

Crinetics Pharmaceuticals Announces Positive Topline Results From Phase 2 Acrobat Edge And Acrobat Evolve Studies Of Paltusotine
Monday, 26 Oct 2020 

Oct 26 (Reuters) - Crinetics Pharmaceuticals Inc ::CRINETICS PHARMACEUTICALS INC - ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 ACROBAT EDGE AND ACROBAT EVOLVE STUDIES OF PALTUSOTINE.CRINETICS PHARMACEUTICALS INC - PALTUSOTINE WAS GENERALLY WELL TOLERATED AMONG THE 60 ACROBAT PARTICIPANTS.CRINETICS PHARMACEUTICALS INC - PRESPECIFIED PRIMARY ENDPOINT IN EDGE WAS ACHIEVED.CRINETICS PHARMACEUTICALS INC - PHASE 3 ACROBAT EDGE AND EVOLVE PROGRAM ON TRACK TO BEGIN IN FIRST HALF OF 2021.  Full Article

Crinetics Pharmaceuticals Plans To Advance Lead Acth Antagonist Into Phase 1 Single-Ascending Dose
Friday, 4 Sep 2020 

Sept 4 (Reuters) - Crinetics Pharmaceuticals Inc ::CRINETICS PHARMACEUTICALS PROVIDES NEW DATA FROM PALTUSOTINE AND ACTH ANTAGONIST DEVELOPMENT PROGRAMS AT EUROPEAN CONGRESS OF ENDOCRINOLOGY.CRINETICS PHARMA - PLANS TO ADVANCE LEAD ACTH ANTAGONIST INTO PHASE 1 SINGLE-ASCENDING DOSE, MULTIPLE-ASCENDING DOSE STUDIES IN LATE 2020 OR EARLY 2021.CRINETICS PHARMACEUTICALS - IN PHASE 1 STUDY, PALTUSOTINE PROVIDED A FAVORABLE MEAN ORAL BIOAVAILABILITY OF 70%.CRINETICS PHARMA - RESULTS OF PHASE 1 STUDY SUGGEST PALTUSOTINE SHOWS PROPERTIES APPROPRIATE FOR CHRONIC ONCE-DAILY ORAL TREATMENT OF ACROMEGALY PATIENTS.  Full Article

Crinetics Pharmaceuticals Reports Q2 2020 Financial Results And Provides Corporate Update
Friday, 7 Aug 2020 

Aug 7 (Reuters) - Crinetics Pharmaceuticals Inc ::CRINETICS PHARMACEUTICALS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $205.2 MILLION AS OF JUNE 30.QTRLY LOSS PER SHARE 53 CENTS.Q2 EARNINGS PER SHARE VIEW $-0.57 -- REFINITIV IBES DATA.  Full Article

Crinetics Pharmaceuticals Reports First Quarter 2020 Financial Results And Provides Corporate Update
Friday, 8 May 2020 

May 8 (Reuters) - Crinetics Pharmaceuticals Inc ::CRINETICS PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.CRINETICS PHARMACEUTICALS INC QTRLY NET LOSS PER SHARE $0.71.CRINETICS PHARMACEUTICALS INC - CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $112.8 MILLION AS OF MARCH 31, 2020.  Full Article

Crinetics Pharmaceuticals Prices Public Offering Of 7.15 Mln Common Stock
Wednesday, 15 Apr 2020 

April 15 (Reuters) - Crinetics Pharmaceuticals Inc ::CRINETICS PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 7.15 MILLION COMMON SHARES PRICED AT $14.00PER SHARE.  Full Article

Crinetics Pharmaceuticals Reports Q4 Loss Per Share Of $0.60
Tuesday, 10 Mar 2020 

March 9 (Reuters) - Crinetics Pharmaceuticals Inc ::CRINETICS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.CRINETICS PHARMACEUTICALS INC QUARTERLY LOSS PER SHARE $0.60.CRINETICS PHARMACEUTICALS INC QUARTERLY GRANT REVENUES $321,000 VERSUS $781,000.CRINETICS PHARMACEUTICALS - EXPECTS THAT CASH, CASH EQUIVALENTS AND INVESTMENTS WILL FUND CURRENT OPERATING PLAN INTO SECOND HALF OF 2021.  Full Article

Crinetics Pharmaceuticals Reports Third Quarter Results
Wednesday, 13 Nov 2019 

Nov 12 (Reuters) - Crinetics Pharmaceuticals Inc ::CRINETICS PHARMACEUTICALS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.CRINETICS PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.60.CRINETICS PHARMACEUTICALS INC - UNRESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $131.7 MILLION AS OF SEPTEMBER 30, 2019.  Full Article

Crinetics Pharmaceuticals Files For Mixed Shelf Of Up To $300 Mln
Wednesday, 14 Aug 2019 

Aug 13 (Reuters) - Crinetics Pharmaceuticals Inc ::CRINETICS PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $300 MILLION – SEC FILING.  Full Article

Crinetics Pharmaceuticals Inc Reports Quarterly Loss Per Share Of $0.51
Wednesday, 14 Aug 2019 

Aug 13 (Reuters) - Crinetics Pharmaceuticals Inc ::CRINETICS PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.CRINETICS PHARMACEUTICALS INC- QTRLY LOSS PER SHARE $0.51.CRINETICS PHARMACEUTICALS - UNRESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $145.0 MILLION AS OF JUNE 30, 2019.  Full Article

Crinetics Pharmaceuticals posts Qtrly Loss Per Share of $0.35
Thursday, 14 Mar 2019 

March 13 (Reuters) - Crinetics Pharmaceuticals Inc ::CRINETICS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.QTRLY LOSS PER SHARE $0.35.  Full Article

BRIEF-Crinetics Pharmaceuticals Receives Orphan Drug Designation For Paltusotine

* CRINETICS PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FOR PALTUSOTINE FOR THE TREATMENT OF ACROMEGALY Source text for Eikon: Further company coverage: